James Ryan Mark, MD, FACS

J. Ryan Mark revised

Associate Professor, Department of Urology

Specialties

  • Urology

Areas of Expertise

Adrenal Tumor, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer

Treatment Focus

Urologic oncology, including advanced, open, endoscopic and robotic surgical techniques.

Distinctions

Treatment Philosophy

It is an incredible privilege to do the work I do and to take care of patients like you. Your trust and well-being are at the core of my team's mission.

As a urologic oncologist, I'm proud to be part of Fox Chase Cancer Center's comprehensive care team dedicated to treating cancers of the urinary and reproductive systems. Our team approach allows us to provide you with the most thorough, personalized, and cutting-edge care possible.

I work closely with a diverse group of specialists including medical oncologists, radiation oncologists, radiologists, pathologists, and others. Together, we develop and implement treatment plans that address all aspects of your health during your cancer journey. This collaborative approach ensures that you receive the most appropriate and effective care for your specific situation.

My role within this team is to bring expertise in surgical treatments, including traditional open, laparoscopic, and robotic techniques. However, our care goes beyond just treating the cancer. We understand the impact that urologic cancer and its treatment can have on your quality of life, including effects on urinary and sexual function. Our team is committed to addressing these concerns with compassion and utmost care.

We're here to guide you through every step of your treatment journey. This includes listening to your concerns, answering your questions, and helping you make informed decisions about your care. Your values and preferences are central to the treatment plans we develop.

Our Fox Chase comprehensive cancer care team is dedicated to supporting you throughout this process, providing you with all the resources and information you need. We strive to make you feel supported, informed, and empowered in your healthcare decisions.

Once again, I want to express that it is a tremendous privilege to be part of amazing Fox Chase - Temple Urologic Institute team and  to care for patients like you. Your trust in us is something we deeply value and respect.
 

Clinical Locations

  • Fox Chase Cancer Center - Chestnut Hill
    8835 Germantown Avenue
    Philadelphia, PA 19118
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Voorhees
    502 Centennial Blvd
    Suite 7
    Voorhees, NJ 08043
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Fort Washington
    515 Pennsylvania Avenue
    Fort Washington, PA 19034
  • Temple University Hospital - Main Campus
    3401 N. Broad Street
    Philadelphia, PA 19140
    Phone: 800-836-7536

Educational Background

  • August 2000-May 2004 B.S. Biology with honors (magna cum laude), University of Missouri, Columbia, Missouri
  • August 2005-May 2009 M.D. Saint Louis University School of Medicine, Saint Louis, Missouri
  • July 2009-June 2010 Internship, General Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
  • July 2010-June 2011 Resident in General Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
  • July 2011-June 2015 Resident in Urologic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
  • July 2015-July 2016 Fellow in Urologic Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina (Now Atrium Health)

Certifications

  • American Board of Urology

Memberships

  • National Societies: 
    American Urological Association 
    American College of Surgeons 
    Endourological Society  
    European Association of Urology  
     
  • Local Societies:  
    Philadelphia Urological Society  
    Philadelphia County Medical Society

Honors & Awards

  • 2019 Honorary Mention – Thomas Jefferson University Hospital Quality Improvement: Application of Alvimopan as a component of Enhanced Recovery After Surgery (ERAS) Protocol for patients undergoing Radical Cystectomy and Diversion (C&D)
  • 2015 Philadelphia Region Robotic Olympics: Urology Gold Medal, Team Jefferson Gold Medal, Tournament Champions
  • 2014 Mid Atlantic AUA 2014 Resident Forum Debate: Best Debater
  • 2003 Phi Beta Kappa 

 

 

Selected Publications

1. Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, Gomella LG. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can J Urol. 2012 Apr;19(2):6227-31. PMID: 22512972.

2. Shenot PJ, Mark JR. Intradetrusor onabotulinumtoxinA injection: how I do it. Can J Urol. 2013;20(1):6649-6655. PMID: 23433140 

3. Mark JR, Kelly DC, Trabulsi EJ, Shenot PJ, Lallas CD. The effects of fatigue on robotic surgery skill training in Urology residents. J Robotic Surg. 2014;8(3):269-275. PMID: 276376894.

4. Mark JR, Gomella LG. Nonpalpable Intratesticular Mass in a Young Man with a History of Contralateral Retractile Testis. Oncology (Williston Park). 2017 Jun 15;31(6):484, 489-91. PMID: 28620904.

5. Mark JR, Hoffman-Censits J, Gomella LG. Basic Concepts in Bladder Cancer Immunotherapy. Am J Hematol Oncol. 2017;13:10.

6. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018;36:4, 414-424. PMID: 29236593

7. Truong H, Savard C, Den RB, Mark JR. Radiation Effect on Male Spermatogenesis and Fertility-The Science and Ethical Consideration of the Oregon and Washington Radiation Experiments on Prison Inmates. Urology. 2018 Nov;121:33-38. PMID: 30107187.

8. Mark JR, Kelly WK, Gomella LG. Re: Multidisciplinary clinical treatment of head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144:460-461. PMID: 29543958

9. Glick L, Chandrasekar T, Hubosky SG, Teplitsky S, Shah M, Leong JY, Ouma G, Mark JR. How I do it: Anticoagulation management for common urologic procedures. Can J Urol. 2020:27(6):10480-10487. PMID: 33325352

10. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019.. J Clin Oncol. 2020;38(4), 2798-2811. PMID: 32516092

11. Chandrasekar T, Glick L, Wong D, Han TM, Leong JY, Yi M, Mark JR, Mann MJ, Trabulsi EJ, Lallas CD. Simple frameshifts in minimally invasive surgery postoperative pain management significantly reduces opiate prescriptions. Can J Urol. 2020:27(3):10250-10256. PMID: 32544049

12. Mann MJ, Calio BP, Mark JR, Chelluri R, Hufnagel E, Reese A, Lallas CD, Trabulsi EJ, Chandrasekar T, Shenot PJ, Halpern E, Gomella LG. Hospital-specific antibiograms and antibiotic prophylaxis for prostate biopsies: a reexamination of AUA recommendations. Can J Urol. 2020;27(1):10099-10104. PMID: 32065866

13. Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, Godwin JL, McCue P, Hurwitz MD, Kelly WK, Lallas CD, Knudsen KE, Gomella LG, Dicker AP, Den RB. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):295-302. PMID: 31719663

14. Chandrasekar T, Han TM, Glick L, Leong JY, Teplitsky S, Noorani R, Holdberg H, Klaassen Z, Wallis CJD, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Setting the standards: Examining research productivity among academic urologists in the USA and Canada in 2019. Euro Urol Focus. 2021;7(2):489-496. PMID: 32113885

15. Salib A, Mark JR. DNA analysis for prostate specimen verification: How I do it. Can J Urol. 2021;28(1):10568-10573. PMID: 33625350

16. Mark JR, McDougal C, Giri V. Genetic testing guidelines and education of health care prostate providers involved in prostate cancer care. Urol Clin N Am. 2021;48:311-322. PMID: 34210487

17. Russo J, McDougal C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann MJ, Mark JR, Mille PJ, Preate D, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN. Pretest genetic education video versus genetic counseling for men considering prostate cancer germline testing: A patient-choice study to address urgent practice needs. JCO Precision Oncology. 2021;5:1377-1386. PMID: 34589662

18. Chandrasekar T, Bowler N, Schneider A, Goldberg H, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Outcomes of active surveillance for men with intermediate risk prostate cancer: A population-based analysis. Urology. 2021;155:101-109. PMID: 34186134

19. Chandrasekar T, Bowler N, Schneider A, Goldberg H, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. AUTHOR REPLY. Urology. 2021 Sep;155:109. PMID: 34488992

20. Uhr A, Glick L, Barron S, Zavodnick J, Mark JR, Shenot PJ, Murphy A. How I do it: PureWick female external catheter: a non-invasive urine management system for incontinent women. Can J Urol. 2021;28(3):10669-10672. PMID: 34129459

21. Shah YB, Clark CB, Shumaker A, Denisenko AA, Alfonsi S, Prebay Z, Schultz J, Mico V, Swaminathan V, Wang R, Mark JR, Trabulsi EJ, Lallas CD, Mann MJ, Goldberg H, Chandrasekar T. Does antithrombotic use enable earlier diagnosis of bladder cancer? A brief institutional assessment. Can J Urol. 2022 Dec;29(6):11391-11393. PMID: 36495582.

22. Gomella PT, Mark JR, Giri VN, Kelly WK, Gomella LG. Guidelines on Germline Testing for Urologic Tumor Syndromes. Eur Urol Focus. 2022;8(3):670-673. PMID: 35803854

23. Loeb S, Cheng HH, Leader A, Gross L, Sanchez-Nolasco T, Byrne N, Wise DR, Hollifeld L, Brown LH, Slater E, Pieczonka C, Gomella LG, Kelly WK, Trabulsi EJ, Handley N, Lallas CD, Chandrasekar TH, Mille P, Mann MJ, Mark JR, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri VN. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials. 2022;119:106821. PMID: 35710085

24. Mark JR, Gomella LG, Lallas CD, Smentkowski KE, Calvaresi A, Handley N, Den RB, Mille P, Tester WJ, Hoffman-Censits J, Dicker AP, Klonicke E, Halpern E, McCue P, Kelly WK, Trabulsi EJ. Enhancing bladder cancer care through the multidisciplinary clinic approach. Can J Urol. 2023 Jun;30(3):11526-11531. PMID: 37344462.

25. Chandrasekar T, Clark CB, Gomella A, Wessner CE, Wang S, Nam K, Liu JB, Forsberg F, Lyshchik A, Halpern E, Mark JR, Lallas CD, Gomella LG, Kania L, Trabulsi EJ, Eisenbrey JR. Volumetric Quantitative Contrast-enhanced Ultrasonography Evaluation of Complex Renal Cysts: An Adjunctive Metric to the Bosniak Classification System to Predict Malignancy. Eur Urol Focus. 2023 Mar;9(2):336-344. PMID: 36319560.

26. Chandrasekar T, Denisenko A, Mico V, McPartland C, Shah Y, Mark JR, Lallas CD, Fonshell C, Danella J, Jacobs B, Lanchoney T, Raman JD, Tomaszewski J, Reese A, Singer EA, Ginzburg S, Smaldone M, Uzzo R, Guzzo TJ, Trabulsi EJ. Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative. Urol Oncol. 2023 Aug;41(8):355.e1-355.e8. Epub 2023 Jun 23. PMID: 37357123.

27. Loeb S, Keith SW, Cheng HH, Leader A, Gross L, Sanchez-Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK, Lallas CD, Handley N, Mille PJ, Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. TARGET: A randomized, noninferiority trial of a pretest, patient-driven genetic education webtool versus genetic counseling for prostate cancer germline testing. Cancer Genetics. (in press)

Related Articles